Construction and validation of a colon cancer prognostic model based on tumor mutation burden-related genes

Daoyang Zou,Tianwen Xu

DOI: https://doi.org/10.1038/s41598-024-53257-z

IF: 4.6

2024-02-05

Scientific Reports

Abstract:Currently, immunotherapy has entered the clinical diagnosis and treatment guidelines for colon cancer, but existing immunotherapy markers cannot predict the effectiveness of immunotherapy well. This study utilized the TCGA-COAD queue to perform differential gene analysis on high and low-mutation burden samples, and screen differentially expressed genes (DEGs). To explore new molecular markers or predictive models of immunotherapy by using DEGs for NMF classification and prognostic model construction. Through systematic bioinformatics analysis, the TCGA-COAD cohort was successfully divided into high mutation burden subtypes and low mutation burden subtypes by NMF typing using DEGs. The proportion of MSI-H between high mutation burden subtypes was significantly higher than that of low mutation burden subtypes, but there was no significant difference in immunotherapy efficacy between the two subtypes. Drug sensitivity analysis showed significant differences in drug sensitivity between the two subtypes. Subsequently, we constructed a prognostic model using DEGs, which can effectively predict patient survival and immunotherapy outcomes. The prognosis and immunotherapy outcomes of the low-risk group were significantly better than those of the high-risk group. The external dataset validation of the constructed prognostic model using the GSE39582 dataset from the GEO database yielded consistent results. At the same time, we also analyzed the TMB and MSI situation between the high and low-risk groups, and the results showed that there was no significant difference in TMB between the high and low-risk groups, but the proportion of MSI-H in the high-risk group was significantly higher than that in the low-risk group. Finally, we conclude that TMB is not a suitable molecular marker for predicting the efficacy of immunotherapy in colon cancer. The newly constructed prognostic model can effectively differentiate the prognosis of colon cancer patients and predict their immunotherapy efficacy.

multidisciplinary sciences

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is that the existing immunotherapy markers are insufficient in predicting the efficacy of immunotherapy for colon cancer. Specifically, although some existing molecular markers such as microsatellite instability (MSI), BRAF and RAS mutation status can predict the prognosis and drug response of patients to a certain extent, clinical heterogeneity still exists. Therefore, more reliable molecular markers or prognostic models need to be found to guide clinical practice. For this purpose, the researchers used the TCGA - COAD cohort to perform differential gene analysis on high - mutation - burden and low - mutation - burden samples, and screened out differentially expressed genes (DEGs). Through non - negative matrix factorization (NMF) classification and prognostic model construction, new molecular markers or predictive models were explored to improve the ability to predict the prognosis and immunotherapy efficacy of colon cancer patients.

The specific objectives of the study include:
1. **Identify differentially expressed genes related to mutation burden**: Through differential gene analysis of high - mutation - burden and low - mutation - burden samples, screen out differentially expressed genes (DEGs) related to mutation burden.
2. **Perform NMF classification based on DEGs**: Use the NMF method to classify colon adenocarcinoma samples and evaluate the immune microenvironment and immune cell infiltration among different mutation - burden subtypes.
3. **Evaluate the immunotherapy efficacy and drug sensitivity of different mutation - burden subtypes**: Through survival analysis, drug - sensitivity analysis and immunotherapy - sensitivity analysis, explore the differences among different mutation - burden subtypes.
4. **Construct and validate a prognostic model**: Use DEGs to construct a prognostic model, and verify the validity of the model through survival analysis, immune microenvironment analysis, immunotherapy - efficacy prediction and drug - sensitivity analysis.
5. **Functional enrichment analysis and immune microenvironment analysis**: Perform functional enrichment analysis on the high - risk and low - risk groups and evaluate the differences in the immune microenvironment and immune cell infiltration.

Through these steps, the study aims to discover a more accurate molecular marker or prognostic model to predict the prognosis and immunotherapy efficacy of colon cancer patients.